Role of tumour markers, cytogenetics.
暂无分享,去创建一个
[1] R. Hruban,et al. The potential diagnostic use of K‐ras codon 12 and p53 alterations in brush cytology from the pancreatic head region , 1998, The Journal of pathology.
[2] R. Hruban,et al. Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. , 1998, Cancer research.
[3] C. Yeo. Pancreatic cancer: 1998 update. , 1998, Journal of the American College of Surgeons.
[4] T. Furukawa,et al. Loss of chromosome 18q is an early event in pancreatic ductal tumorigenesis. , 1998, Cancer research.
[5] O. Nilsson,et al. Summary Report on the ISOBM TD-6 Workshop: Analysis of 20 Monoclonal Antibodies against Sialyl Lewisa and Related Antigens , 1998, Tumor Biology.
[6] R. Hruban,et al. Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. , 1998, The American journal of pathology.
[7] M Monden,et al. Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] J. Furuse,et al. Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer. , 1998, Hepato-gastroenterology.
[9] R. Sherwood,et al. The Effect of Benign and Malignant Liver Disease on the Tumour Markers CA19-9 and CEA , 1998, Annals of clinical biochemistry.
[10] R. Hruban,et al. Can K-ras codon 12 mutations be used to distinguish benign bile duct proliferations from metastases in the liver? A molecular analysis of 101 liver lesions from 93 patients. , 1997, The American journal of pathology.
[11] C. Moskaluk,et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. , 1997, Cancer research.
[12] S. Goodman,et al. Tumor-suppressive pathways in pancreatic carcinoma. , 1997, Cancer research.
[13] M. Imamura,et al. Clinical significance of serum p53 antigen in patients with pancreatic carcinomas. , 1997, Gut.
[14] J. Furuse,et al. CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. , 1997, Hepato-gastroenterology.
[15] S. Leach,et al. Detection of mutated c-Ki-ras in the bile of patients with pancreatic cancer. , 1997, Anticancer research.
[16] S. Yoshida,et al. Detection of K‐ras gene mutations at codon 12 in the pancreatic juice of patients with intraductal papillary mucinous tumors of the pancreas , 1997, Cancer.
[17] J. Rhodes,et al. Prospective study of CAM 17·1/WGA mucin assay for serological diagnosis of pancreatic cancer , 1997, The Lancet.
[18] T. Ørntoft,et al. Influence of Lewis α1-3/4-L-Fucosyltransferase (FUT3) Gene Mutations on Enzyme Activity, Erythrocyte Phenotyping, and Circulating Tumor Marker Sialyl-Lewis a Levels* , 1996, The Journal of Biological Chemistry.
[19] S. Gansauge,et al. CAM 17.1--a new diagnostic marker in pancreatic cancer. , 1996, British Journal of Cancer.
[20] C. Moskaluk,et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. , 1996, Cancer research.
[21] H. Bruckner,et al. Tumor markers in patients with pancreatic carcinoma , 1996, Cancer.
[22] Yingze Zhang,et al. A gene for hereditary pancreatitis maps to chromosome 7q35. , 1996, Gastroenterology.
[23] Scott E. Kern,et al. DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1 , 1996, Science.
[24] M. Plebani,et al. Tumor Markers in the Diagnosis, Monitoring and Therapy of Pancreatic Cancer: State of the Art , 1995, The International journal of biological markers.
[25] C. Haglund,et al. Prognostic significance of serum CA 242 in pancreatic cancer. A comparison with CA 19-9. , 1995, Anticancer research.
[26] P. Laurent-Puig,et al. Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases. , 1995, Gut.
[27] Roger Williams,et al. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. , 1995, Gastroenterology.
[28] H. Friess,et al. p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness. , 1994, Anticancer research.
[29] S. Kawa,et al. Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer. , 1994, British Journal of Cancer.
[30] C. Haglund,et al. CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA. , 1994, British Journal of Cancer.
[31] R. Hruban,et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. , 1994, Cancer research.
[32] R. Hruban,et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. , 1994, Cancer research.
[33] S. Goodman,et al. Overexpression of p53 protein in adenocarcinoma of the pancreas. , 1994, American journal of clinical pathology.
[34] J. Cameron,et al. Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. , 1994, The American journal of pathology.
[35] G. Gores,et al. Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. , 1993, Mayo Clinic proceedings.
[36] S. Goodman,et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. , 1993, The American journal of pathology.
[37] H. Friess,et al. p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. , 1993, Cancer letters.
[38] C. Ker,et al. Assessment of serum and bile levels of CA19‐9 and CA125 in cholangitis and bile duct carcinoma , 1991, Journal of gastroenterology and hepatology.
[39] D. Iliopoulos,et al. Serum CEA and CA 19‐9: Potential future diagnostic or screening tests for gallbladder cancer? , 1990, International journal of cancer.
[40] H. Aste,et al. CA 19‐9 and CA 50 in Benign and malignant pancreatic and biliary diseases , 1988, Cancer.
[41] R H Hruban,et al. Genetics of pancreatic cancer. From genes to families. , 1998, Surgical oncology clinics of North America.
[42] W. Schlosser,et al. Prognostic value of CA 19-9 serum course in pancreatic cancer. , 1998, Hepato-gastroenterology.
[43] R. Hruban,et al. K‐ras mutations in the duodenal fluid of patients with pancreatic carcinoma , 1998, Cancer.
[44] H. Gogas,et al. Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? , 1998, British Journal of Cancer.
[45] H. Friess,et al. Molecular versus conventional markers in pancreatic cancer. , 1997, Digestion.
[46] Y. Shiratori,et al. Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. , 1996, Gastroenterology.
[47] N. Lemoine,et al. Ki-ras oncogene activation in preinvasive pancreatic cancer. , 1992, Gastroenterology.
[48] R. Lamerz. CA 19–9, GICA (Gastrointestinal Cancer Antigen) , 1992 .
[49] S. Sironi,et al. Pancreatic cancer versus chronic pancreatitis: diagnosis with CA 19-9 assessment, US, CT, and CT-guided fine-needle biopsy. , 1991, Radiology.